Febrile Neutropenia in a Metastatic Melanoma Patient Treated with Ipilimumab - Case Report

被引：18

作者：

Wozniak, Sebastian ^{[1
]}

Mackiewicz-Wysocka, Malgorzata ^{[2
]}

Krokowicz, Lukasz ^{[3
]}

Kwinta, Lukasz ^{[1
]}

Mackiewicz, Jacek ^{[4
,5
,6
]}

机构：

[1] Greater Poland Canc Ctr, Dept Chemotherapy, Poznan, Poland

[2] Poznan Univ Med Sci, Dept Dermatol, Poznan, Poland

[3] Univ Med Sci, Dept Gen Endocrinol & Gastroenterol Oncol Surg, Poznan, Poland

[4] Univ Med Sci, Med Biotechnol, PL-61051 Poznan, Poland

[5] Greater Poland Canc Ctr, Dept Diagnost & Canc Immunol, Poznan, Poland

[6] Malgorzata Med Ctr, Dept Med Oncol, Srem, Poland

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2015年 / 38卷 / 03期

关键词：

Ipilimunnab; Anti-CTLA4; Immunotherapy; Melanoma; EFFICACY;

D O I：

10.1159/000377650

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: lpilimumab is a fully human monoclonal antibody (mAb) targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4). lpilimumab is currently approved in the U.S. and Europe for the treatment of metastatic melanoma in the first- and second-line treatment. Treatment with ipilinnumab is linked to immune-related adverse events (irAEs) occurring in the majority of patients. These specific AEs include dermatitis, gastrointestinal disorders (diarrhea, colitis), hepatitis, hypophysitis, hypothyroidism, neuropathy, and iritis/inflammation of the ciliary body. Case Report: We report a case of febrile neutropenia with agranulocytosis in the blood smear of a 35-year-old metastatic melanoma patient treated with ipilimumab 3 mg/kg. Conclusion: This AE was probably caused by antineutrophil antibodies associated with ipilimumab treatment. To our knowledge this is the first case report of febrile neutropenia in a metastatic melanoma patient treated with ipilimumab 3 mg/kg.

引用

页码：105 / 108

页数：4

共 50 条

[1] Case Report: Response to Ipilimumab in a Patient With HIV With Metastatic Melanoma
Burke, Matthew M.
Kluger, Harriet M.
Golden, Marjorie
Heller, Kevin N.
Hoos, Axel
Sznol, Mario
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (32) : E792 - E794
[2] Enterocolitis in a Patient Being Treated With Ipilimumab for Metastatic Melanoma
Koch, Christine
Paetzold, Sylvie
Trojan, Joerg
[J]. GASTROENTEROLOGY, 2012, 143 (02) : 298 - 505
[3] Panhypopituitarism in metastatic melanoma patient treated with ipilimumab and pembrolizumab
Goto, Haruka
Kasuya, Akira
Imura, Kie
Miyazawa, Hidehiko
Fujiyama, Toshiharu
Kakizawa, Keisuke
Tokura, Yoshiki
[J]. JOURNAL OF CUTANEOUS IMMUNOLOGY AND ALLERGY, 2019, 2 (02) : 60 - 61
[4] Treatment with Ipilimumab: A Case Report of Complete Response in a Metastatic Malignant Melanoma Patient
Addeo, Alfredo
Rinaldi, Ciro Roberto
[J]. CASE REPORTS IN ONCOLOGY, 2013, 6 (02): : 285 - 288
[5] Aplastic anemia secondary to nivolumab and ipilimumab in a patient with metastatic melanoma: a case report
D. E. Meyers
W. F. Hill
A. Suo
V. Jimenez-Zepeda
T. Cheng
N. A. Nixon
[J]. Experimental Hematology & Oncology, 7
[6] Aplastic anemia secondary to nivolumab and ipilimumab in a patient with metastatic melanoma: a case report
Meyers, D. E.
Hill, W. F.
Suo, A.
Jimenez-Zepeda, V.
Cheng, T.
Nixon, N. A.
[J]. EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2018, 7
[7] Letter: cytomegalovirus colitis in a patient treated with ipilimumab for metastatic melanoma
Bossa, F.
Perri, F.
Niro, G.
Parente, P.
Graziano, P.
Andriulli, A.
[J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 43 (01) : 174 - 175
[8] Diarrhoea in a patient with metastatic melanoma:Ipilimumab ileocolitis treated with infliximab
Rob ME Slangen
Alfonsus JM van den Eertwegh
Adriaan A van Bodegraven
Nanne KH de Boer
[J]. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2013, (03) : 80 - 82
[9] AntineoplasticsNeutropenia and febrile neutropenia in an elderly patient: case report
[J]. Reactions Weekly, 2013, 1440 (1) : 7 - 7
[10] IrinotecanDiarrhoea and febrile neutropenia in an elderly patient: case report
[J]. Reactions Weekly, 2009, 1255 (1) : 20 - 20

← 1 2 3 4 5 →